<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01417221</url>
  </required_header>
  <id_info>
    <org_study_id>SWAN-HT</org_study_id>
    <nct_id>NCT01417221</nct_id>
  </id_info>
  <brief_title>Renal Sympathetic Modification in Patients With Essential Hypertension</brief_title>
  <official_title>Renal Sympathetic Modification in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Second Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zunyi Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Second Affiliated Hospital of Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe the incident of composite cardiovascular events after&#xD;
      renal sympathetic modification using THERMOCOOL® catheter in patients with essential&#xD;
      hypertension, and evaluate safety and efficacy of the intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertension is a common cardiovascular disease, and is also an important risk factor for&#xD;
      heart-brain-renal diseases, with relatively low controlled rate. Traditional pharmacological&#xD;
      therapies are used in clinical practice without breakthrough for long time. Previous studies&#xD;
      confirmed that sympathetic nerves activity contributed to development and perpetuation of&#xD;
      hypertension. Renal ablation for sympathetic modification is a new method which is proved to&#xD;
      be effective in decreasing sympathetic nerves activity. We assume that modifying renal&#xD;
      sympathetic activity by ablation is effective and safe in treatment of hypertension. This&#xD;
      trial is going to recruit 200 patients (Ablation group VS Control group = 1:1) with a&#xD;
      follow-up duration of 3 years. Patients in ablation group will receive additional necessary&#xD;
      anti-hypertensive medications besides expectant intervention, and patients in control group&#xD;
      will receive appropriate anti-hypertensive medications only. We aim to observe the incident&#xD;
      of composite cardiovascular events after renal sympathetic modification using THERMOCOOL®&#xD;
      catheter in patients with hypertension, and evaluate safety and efficacy of the intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 2011</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>composite cardiovascular events</measure>
    <time_frame>three years</time_frame>
    <description>Comprising myocardial infarction, stroke, heart failure, sudden death</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>renal sympathetic modification</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal artery ablation to modify sympathetic activity in patients with essential hypertension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Absolute medicine therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Maintenance of anti-hypertensive medications only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>renal sympathetic modification</intervention_name>
    <description>Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure</description>
    <arm_group_label>renal sympathetic modification</arm_group_label>
    <other_name>renal denervation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years old, and ≤ 75 years old of age&#xD;
&#xD;
          -  more than half a year history of hypertension, except for valvular heart disease&#xD;
&#xD;
          -  recently at least three times office blood pressure suggest systolic blood pressure of&#xD;
             140mmHg or more and/or a diastolic blood pressure of 90mmHg or more&#xD;
&#xD;
          -  estimated glomerular filtration rate (eGFR) of ≥ 45mL/min&#xD;
&#xD;
          -  is competent and willing to provide written, informed consent to participate in this&#xD;
             clinical study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  secondary hypertension&#xD;
&#xD;
          -  isolated systolic hypertension&#xD;
&#xD;
          -  estimated glomerular filtration rate (eGFR) of &lt; 45mL/min&#xD;
&#xD;
          -  has the history of renal restenosis or renal stents implantation&#xD;
&#xD;
          -  has experienced AMI (old myocardial infarction is not excluded), unstable angina&#xD;
             pectoris, cerebrovascular accidents, and alimentary tract hemorrhage within 3 months&#xD;
&#xD;
          -  patients with sick sinus syndrome&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  mental disorders&#xD;
&#xD;
          -  patients that have allergy to contrast agent&#xD;
&#xD;
          -  patients that do not go with follow-up&#xD;
&#xD;
          -  others such as researcher considers it is not appropriate to be included into the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuehui Yin, MD</last_name>
    <phone>0086-13508335502</phone>
    <email>yinyh63@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>2ndChongqingMU</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuehui Yin, MD</last_name>
      <phone>0086-23-63693766</phone>
      <email>yinyh63@163.com</email>
    </contact>
    <investigator>
      <last_name>Yuehui Yin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 15, 2011</study_first_submitted>
  <study_first_submitted_qc>August 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2011</study_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Second Affiliated Hospital of Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Yuehui Yin</investigator_full_name>
    <investigator_title>Director and Professor, Dept. of Cardiology, the second affiliated hospital of Chongqing Medical University, Chongqing Cardiac arrhythmias service center</investigator_title>
  </responsible_party>
  <keyword>renal artery</keyword>
  <keyword>sympathetic nerves</keyword>
  <keyword>modification</keyword>
  <keyword>essential hypertension</keyword>
  <keyword>primary hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

